CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 109 enrolled
Drug / intervention
INGEVITY+™ Pace/Sense Leaddevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04346537
NCT04346537N/ACompleted
CompareCT.gov

INGEVITY+ Active Fixation Pace/Sense Lead Clinical Study

Boston Scientific Corporation·observational·Posted Apr 15, 2020·Updated Jul 14, 2022

In Brief

An observational study evaluating INGEVITY+™ Pace/Sense Lead for Bradycardia. Completed, enrolled 109 participants across 13 sites.

Detailed Summary

The objective of this study is it to confirm the safety and effectiveness of the INGEVITY+ Active Fixation Pace/Sense Lead.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBradycardia
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedApr 15, 2020
Enrollment StartAug 6, 2020
Primary CompletionMar 1, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 6.2 years ago

Interventions

INGEVITY+™ Pace/Sense Leaddevice

The INGEVITY+ lead is indicated for chronic pacing and sensing in the right atrium and/or right ventricle when used with a compatible pulse generator.